Management of salivary gland tumors

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1161-1168

  Andry, Guy ^a   Hamoir, Marc ^b   Locati, Laura D ^c   Licitra, Lisa ^c   Langendijk, Johannes A ^d  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

adenocarcinoma; adenoid cystic; chemotherapy; mucoepidermoid; pleomorphic adenoma; radiation therapy; salivary gland tumors; surgery; targeted molecular therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BORTEZOMIB; CARBON; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; IMATINIB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTON; SORAFENIB; TRASTUZUMAB; VORINOSTAT;

ADD ON THERAPY; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EXCISION; EXTERNAL BEAM RADIOTHERAPY; FACIAL NERVE; HUMAN; INOPERABLE CANCER; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PAROTID GLAND CARCINOMA; PAROTID GLAND TUMOR; RECURRENT CANCER; REVIEW; SALIVARY GLAND CANCER; SALIVARY GLAND TUMOR; SURGICAL TECHNIQUE; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; DISSECTION; FACIAL NERVE INJURIES; HUMANS; INTRAOPERATIVE COMPLICATIONS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY; RISK ADJUSTMENT; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84867929227     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.92     Document Type: Review

References (55)

1. Chandana SR, Conley BA. Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev. Anticancer Ther. 8(4), 645-652 (2008). (Pubitemid 351818358)
2. Wening BM. Classification of nonneoplastic salivary gland lesions and classification of neoplasms of salivary glands. Atlas Head Neck Pathol. 541 (2008).
3. Sobin LH, Gospodarowics MK, Wittekind CH. TNM Classification of Malignant Tumours (7th Edition). UICC, 54-57 (2009).
4. Boukheris H, Curtis RE, Land CE, Dores GM. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol. Biomarkers Prev. 18(11), 2899-2906 (2009).
5. Muenscher A, Diegel T, Jaehne M, Ussmüller J, Koops S, Sanchez-Hanke M. Benign and malignant salivary gland diseases in children: a retrospective study of 549 cases from the Salivary Gland Registry, Hamburg. Auris. Nasus. Larynx 36(3), 326-331 (2009).
6. Ishibashi M, Fujii S, Kawamoto K et al. The ability to identify the intraparotid facial nerve for locating parotid gland lesions in comparison to other indirect landmark methods: evaluation by 3.0 T MR imaging with surface coils. Neuroradiology 52(11), 1037-1045 (2010).
7. Spiro JD, Spiro RH. Cancer of the parotid gland: role of 7th nerve preservation. World J. Surg. 27(7), 863-867 (2003). (Pubitemid 37022403)
8. Wittekindt C, Streubel K, Arnold G et al. Recurrent Pleomorphic Adenoma of the Parotid Gland: Analysis of 108 Consecutive Patients. Wiley InterScience, NY, USA doi:10.1002/hed.20613 (2007). (Pubitemid 350303669)
9. Shekar K, Singh M, Godden D, Puxeddu R, Brennan PA. Recent advances in the management of salivary gland disease. Br. J. Oral Maxillofac. Surg. 47(8), 594-597 (2009).
10. Nouraei SA, Ferguson MS, Clarke PM et al. Metastasizing pleomorphic salivary adenoma. Arch. Otolaryngol. Head Neck Surg. 132(7), 788-793 (2006). (Pubitemid 44086445)
11. Anderson RG. Facial nerve disorders and surgery. Selected Readings in Plastic Surgery. University of Texas Health Science Center at Dallas, TX, USA (2006).
12. Bradley PJ, Zbaeren P. Neck metastasis. In: Salivary Gland Disorders and Diseases: Diagnosis and Management. Thieme D (Ed.). Georg Thieme Verlag, Stuttgart, Germany, 330-331 (2011).
13. Bhattacharyya N, Fried MP. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch. Otolaryngol. Head Neck Surg. 128(8), 904-908 (2002). (Pubitemid 34856259)
14. Razfar A, Heron DE, Branstetter BF 4th, Seethala RR, Ferris RL. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 120(4), 734-738 (2010).
15. Carrillo JF, Maldonado F, Carrillo LC et al. Prognostic factors in patients with minor salivary gland carcinoma of the oral cavity and oropharynx. Head Neck 33(10), 1406-1412 (2011).
16. Pohar S, Gay H, Rosenbaum P et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int. J. Radiat. Oncol. Biol. Phys. 61(1), 112-118 (2005). (Pubitemid 40039112)
17. Terhaard CH, Lubsen H, Rasch CR et al.; Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int. J. Radiat. Oncol. Biol. Phys. 61(1), 103-111 (2005). (Pubitemid 40039111)
18. Tanvetyanon T, Qin D, Padhya T et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch. Otolaryngol. Head Neck Surg. 135(7), 687-692 (2009).
19. Tanvetyanon T, Padhya T, McCaffrey J et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J. Clin. Oncol. 27(12), 1983-1991 (2009).
20. Schoenfeld JD, Sher DJ, Norris CM Jr et al. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 308-314 (2012).
21. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103(12), 2544-2550 (2005). (Pubitemid 40800533)
22. Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 66(4), 1044-1050 (2006). (Pubitemid 44633522)
23. Huber PE, Debus J, Latz D et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother. Oncol. 59(2), 161-167 (2001). (Pubitemid 32452309)
24. Pommier P, Liebsch NJ, Deschler DG et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch. Otolaryngol. Head Neck Surg. 132(11), 1242-1249 (2006). (Pubitemid 44800140)
25. Schulz-Ertner D, Nikoghosyan A, Didinger B et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 104(2), 338-344 (2005). (Pubitemid 40993261)
26. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 12(8), 815-824 (2011).
27. Haddad R, Colevas AD, Krane JF et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A Phase II study. Oral Oncol. 39(7), 724-727 (2003). (Pubitemid 36930120)
28. Jaspers HC, Verbist BM, Schoffelen R et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J. Clin. Oncol. 29(16), e473-e476 (2011).
29. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23(24), 5474-5483 (2005).
30. ArgirisA, GhebremichaelM, BurtnessB, AxelrodRS, DecontiRC, ForastiereAA. A Phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).Cancer117(15), 3374-3382(2011).
31. Anzick SL, Chen WD, Park Y et al. Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Genes. Chromosomes Cancer 49(1), 59-69 (2010).
32. Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK. CRTC1/ MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes. Chromosomes Cancer 46(7), 708-715 (2007). (Pubitemid 46802338)
33. Martins C, Cavaco B, Tonon G, Kaye FJ, Soares J, Fonseca I. A study of MECT1- MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands. J. Mol. Diagn. 6(3), 205-210 (2004). (Pubitemid 39136647)
34. Behboudi A, Enlund F, Winnes M et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes. Chromosomes Cancer 45(5), 470-481 (2006).
35. Okabe M, Miyabe S, Nagatsuka H et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin. Cancer Res. 12(13), 3902-3907 (2006). (Pubitemid 44078073)
36. Fehr A, Röser K, Belge G, Löning T, Bullerdiek J. A closer look at Warthin tumors and the t(11;19). Cancer Genet. Cytogenet. 180(2), 135-139 (2008).
37. Locati LD, Perrone F, Losa M et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 45(11), 986-990 (2009).
38. Sequeiros-Santiago G, García-Carracedo D, Fresno MF, Suarez C, Rodrigo JP, Gonzalez MV. Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol. Rep. 21(5), 1215-1222 (2009).
39. Vidal L, Tsao MS, Pond GR et al. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31(8), 1006-1012 (2009).
40. Seethala RR, Cieply K, Barnes EL, Dacic S. Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation. Arch. Pathol. Lab. Med. 135(1), 123-130 (2011).
41. Vila L, Liu H, Al-Quran SZ, Coco DP, Dong HJ, Liu C. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod. Pathol. 22(10), 1296-1302 (2009).
42. Negri T, Tamborini E, Dagrada GP et al. TRK-A, HER-2/neu, and KIT expression/ activation profiles in salivary gland carcinoma. Transl. Oncol. 1(3), 121-128 (2008).
43. Seethala RR, Dacic s, Cieply K et al. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am. J. Surg. Pathol. 34(8), 1106-1121 (2010).
44. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc. Natl Acad. Sci. USA 106(44), 18740-18744 (2009).
45. Mitani Y, Li J, Rao PH et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin. Cancer Res. 16(19), 4722-4731 (2010).
46. Stenman G, Andersson MK, Andrén Y. New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle 9(15), 2986-2995 (2010).
47. Dahse R, Kromeyer-Hauschild K, Berndt A, Kosmehl H. No incidence of BRAF mutations in salivary gland carcinomas - implications for anti-EGFR therapies. J. Biomed. Biotechnol. 2009, 13-15 (2009).
48. Lujan B, Hakim S, Moyano S et al. Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br. J. Cancer 103(4), 510-516 (2010).
49. Press MF, Pike MC, Hung G et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 54(21), 5675-5682 (1994). (Pubitemid 24346266)
50. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin. Cancer Res. 16(8), 2266-2274 (2010).
51. Locati LD, Bossi P, Perrone F et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a Phase II study. Oral Oncol. 45(7), 574-578 (2009).
52. Glisson BS, Blumenschein G, Francisco M et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J. Clin. Oncol. 23(16 Suppl.), Abstract 5532 (2005).
53. Agulnik M, Cohen EW, Cohen RB et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol. 25(25), 3978-3984 (2007). (Pubitemid 47477277)
54. Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II consortium study. J. Clin. Oncol. 23(3), 585-590 (2005). (Pubitemid 46224236)
55. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A Phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 43(1), 33-36 (2007). (Pubitemid 46162246)